Yunkang Group Limited (2325.HK)
HKSE · HKD · Healthcare · Diagnostics & Research
HK$0.64 (+6.67%) as of
Key statistics
- Market cap
- 374.62M
- P/E (TTM)
- 5.33
- EPS (TTM)
- 0.120
- Dividend yield
- 0.00%
- 52-week range
- 0.440 – 1.250
- Beta
- -0.72
- Revenue (TTM)
- 540.93M
- Profit margin
- 11.22%
- Analyst target
- HK$10.91
- Volume
- 740.00k
About Yunkang Group Limited
Yunkang Group Limited operates as a medical operation service provider in the People's Republic of China. The company offers diagnostic testing services for medical institution alliances, including setting up or upgrading diagnostic centers, the establishment of standard operating procedures for diagnostic testing, diagnostic consultation and staff training, procurement of equipment, smart internet of things, and logistics assistance. It also provides diagnostic outsourcing services comprising pathology tests; infectious disease diagnostic tests; and genetic reproduction and screening tests. In addition, the company offers routine diagnostic tests for chronic kidney, blood, autoimmune, endocrine metabolism, and other diseases. Further, it provides technology platforms, including AI + healthcare; high-throughput sequencing technology platform; PCR technology platform; digital pathology remote diagnosis platform; and other technology platforms. The company provides its services through independent clinical laboratories and on-site diagnostic centers. Yunkang Group Limited was founded in 2008 and is headquartered in Guangzhou, the People's Republic of China.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Guangzhou, China
- Employees
- 1,008
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.